Tom A. John

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Navigating Evidence Standards: Stakeholder Perspectives on External Controls and Randomization in Cancer Trials.

Navigating Evidence Standards: Stakeholder Perspectives on External Controls and Randomization in Cancer Trials.

Journal: Asia-Pacific journal of clinical oncology
Published: February 23, 2026

Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Journal: Future oncology (London, England)
Published: February 18, 2026

Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study.

Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study.

Journal: JTO clinical and research reports
Published: August 18, 2025

Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry.

Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry.

Journal: JTO clinical and research reports
Published: August 06, 2025

Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia.

Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia.

Journal: Thoracic cancer
Published: June 04, 2025

Development of a clinical core outcome set to evaluate lung cancer rehabilitation.

Development of a clinical core outcome set to evaluate lung cancer rehabilitation.

Journal: ERJ open research
Published: January 14, 2025

A Response to "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".

A Response to "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 16, 2024

Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study.

Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study.

Journal: Clinical lung cancer
Published: December 01, 2024

EGFR mutation testing across the osimertinib clinical program.

EGFR mutation testing across the osimertinib clinical program.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 07, 2024

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Journal: Frontiers in oncology
Published: September 02, 2024

Equipoise Remains a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC.

Equipoise Remains a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 29, 2024

The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.

The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 06, 2023
Showing 1-12 of 31

Last Updated: 09/26/2026